BioNTech SE (BNTX)

[DewDiligence]

PFE/BNTX start phase-1 trial of Omicron vaccine:

https://finance.yahoo.com/news/pfizer-biontech-initiate-study-evaluate-114500326.html

The study will evaluate up to 1,420 participants across the three cohorts:

• Cohort #1 (n = 615): Received two doses of the current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in the study, participants will receive one or two doses of the Omicron-based vaccine

• Cohort #2 (n = 600): Received three doses of the current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in the study, participants will receive one dose of the current Pfizer-BioNTech COVID-19 vaccine or the Omicron-based vaccine

• Cohort #3 (n=205): Vaccine-naïve participants will receive three doses of the Omicron-based vaccine